Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.

GlaxoSmithKline10 enrolled

Overview

The purpose of this study is to evaluate the safety and immunogenicity of two doses of GSK Biologicals' 11 PCV vaccine when given to healthy subjects aged 18 to 40 years .

The study is open and subjects will receive two vaccine doses of GSK Biologicals' 11 PCV vaccine. Five blood samples will be taken: prior to and one month after each vaccine dose, and 2 weeks after dose 2.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Prophylactic Pneumococcal Diseases

Interventions

pneumococcal vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy male or female between 18 and 40 years of age * 23-valent pneumococcal polysaccharide vaccine naive adults. Exclusion Criteria: * Previous vaccination against Streptococcus pneumoniae. * History of pneumonia within 3 years prior to the first vaccination * Any confirmed or suspected immunosuppressive or immunodeficient condition * All malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders diagnosed or treated actively during the past 5 years. * Subjects with documented anaemia or iron-deficiency (Hemoglobin level more than 10% below lower limit of normal) * History of administration of an experimental/licensed vaccine containing similar adjuvants. * History of chronic alcohol consumption and/or drug abuse. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions.

Locations (1)

GSK Investigational Site

Ghent, Belgium

Outcomes

Primary Outcomes

Occurrence of solicited local & general symptoms (Day 0-7) and unsolicited symptoms (Day 0-30) after vaccination. Occurrence of serious adverse events during the entire study;

Frequencies of IgG PS-specific plasma cells (by B-cell ELISPOT) for 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) prior to & 1 month post dose 1, 2 weeks & 1 month post dose 2

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.